Cellectar Biosciences Inc (CLRB)

May 20, 2026

Cellectar Biosciences Bets on Iopofosine Breakthrough - TipRanks

May 20, 2026

May 19, 2026

Cellectar Biosciences Files for Secondary Offering of Common Shares - Moomoo

May 19, 2026

May 19, 2026

Cellectar (NASDAQ: CLRB) S-1 details 51.2M-share resale and major warrant overhang - Stock Titan

May 19, 2026

May 18, 2026

Cellectar Biosciences Announces Board Changes and New Director - TipRanks

May 18, 2026

May 18, 2026

Cellectar Biosciences (NASDAQ: CLRB) seeks approval for warrants and plan increase - Stock Titan

May 18, 2026

May 18, 2026

Cellectar Biosciences appoints Andrew Gu to board; Stefan D. Loren to step down, join as consultant - TradingView

May 18, 2026

May 18, 2026

Cellectar (NASDAQ: CLRB) reshapes board with Loren exit and Andrew Gu appointment - Stock Titan

May 18, 2026

May 17, 2026

User | dailytimesleader.comCellectar Biosciences, Inc.Common Stock (Nasdaq:CLRB) Stock Quote - FinancialContent

May 17, 2026

May 17, 2026

Cellectar (CLRB) phase 2b data shows durable responses in Waldenström macroglobulinemia - MSN

May 17, 2026

May 16, 2026

CLRB Assumed by Ladenburg Thalmann -- Rating Set to Buy - GuruFocus

May 16, 2026

May 15, 2026

Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $10 - Moomoo

May 15, 2026

May 15, 2026

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2026 Earnings Call Transcript - Insider Monkey

May 15, 2026

May 15, 2026

Cellectar Biosciences Reports Positive Phase 2b Data for Iopofosine I 131 in Waldenström Macroglobulinemia and Secures $140M Financing for Phase 3 Trial and FDA Filing - Minichart

May 15, 2026

May 15, 2026

Cellectar Biosciences, Inc.Common Stock (NQ: CLRB - FinancialContent

May 15, 2026

May 15, 2026

What's Going With Cellectar Biosciences Stock On Wednesday? - MSN

May 15, 2026

May 14, 2026

Cellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus

May 14, 2026

May 14, 2026

Cellectar Biosciences Signals Pivotal Turn in Earnings Call - TipRanks

May 14, 2026

May 14, 2026

Cellectar Biosciences Q1 2026 Earnings Call Transcript - MarketBeat

May 14, 2026

May 14, 2026

Cellectar Biosciences (CLRB) Reports Positive Phase IIb Results and Plans FDA Filing - GuruFocus

May 14, 2026

May 14, 2026

Cellectar Biosciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance

May 14, 2026

May 14, 2026

Cellectar Biosciences, Inc. Q1 2026 Financial Report, Forward-Looking Statements, and SEC Filings - Minichart

May 14, 2026

May 14, 2026

Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates - Investing News Network

May 14, 2026

May 14, 2026

Cellectar plans phase III start in late Q4 2026 as it outlines potential WM approval in the second half of 2027 - MSN

May 14, 2026

May 14, 2026

Earnings call transcript: Cellectar Biosciences Q1 2026 shows progress - Investing.com UK

May 14, 2026

May 14, 2026

Is Cellectar Biosciences (CLRB) Attractively Valued After Q1 202 - GuruFocus

May 14, 2026

May 14, 2026

Cellectar Biosciences Releases Q1 2026 Financial Results - AlphaStreet

May 14, 2026

May 14, 2026

Cellectar Biosciences Q1 2026: Loss Narrows 29.6% to -$1.33/Share - AlphaStreet

May 14, 2026

May 14, 2026

Earnings call transcript: Cellectar Biosciences Q1 2026 shows progress By Investing.com - Investing.com Nigeria

May 14, 2026

May 14, 2026

CLRB: Strong clinical results and $140M financing drive late-stage execution and regulatory momentum - TradingView

May 14, 2026

May 14, 2026

Cellectar (CLRB) Secures $140 Million Financing for Regulatory M - GuruFocus

May 14, 2026

May 14, 2026

Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call - Benzinga

May 14, 2026

May 14, 2026

Cellectar Biosciences 1Q Loss $5.65M >CLRB - Moomoo

May 14, 2026

May 14, 2026

CLRB: Strong efficacy in r/r WM and robust financing position clinical programs for key milestones - TradingView

May 14, 2026

May 14, 2026

Cellectar Biosciences reports Q1 2026 net loss of $5.65M; cash $8.3M before $31M financing - TradingView

May 14, 2026

May 14, 2026

Cellectar Biosciences (CLRB) posts Q1 2026 loss and secures up to $140M - Stock Titan

May 14, 2026

May 14, 2026

Cellectar Biosciences, Inc. Q1 2026: Net loss $(5.65M), EPS $(1.33) — 10-Q Summary - TradingView

May 14, 2026

May 14, 2026

Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 14, 2026

May 14, 2026

Cellectar Biosciences (NASDAQ: CLRB) posts Q1 loss and flags going-concern risk - Stock Titan

May 14, 2026

May 14, 2026

CLRB: Net loss narrowed, clinical data for iopofosine I 131 remained strong, and $35M was raised for Phase 3 - TradingView

May 14, 2026

May 12, 2026

Cellectar Biosciences Inc expected to post a loss of $1.88 a shareEarnings Preview - TradingView

May 12, 2026

May 11, 2026

Cellectar Biosciences COO Jarrod Longcor buys $24,998 in stock - Investing.com UK

May 11, 2026

May 11, 2026

Cellectar Biosciences CEO buys $24,998 in company stock - Investing.com UK

May 11, 2026

May 11, 2026

Cellectar Biosciences CEO buys $24,998 in company stock By Investing.com - Investing.com South Africa

May 11, 2026

May 11, 2026

Cellectar Biosciences COO Jarrod Longcor buys $24,998 in stock By Investing.com - Investing.com Canada

May 11, 2026

May 11, 2026

Cellectar (NASDAQ: CLRB) COO boosts stake with common stock and warrant buys - Stock Titan

May 11, 2026

May 11, 2026

Cellectar (CLRB) CEO reports open-market stock and warrant buys - Stock Titan

May 11, 2026

May 11, 2026

Stonepine, Jon Plexico disclosed 9.9% stake in Cellectar Biosciences (CLRB) - Stock Titan

May 11, 2026

May 11, 2026

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026 - Investing News Network

May 11, 2026